APO Research
Talk to an analyst

APO RESEARCH · REPORT

Circulating Tumor Cells

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

Selected research

Market Analysis & Forecast

Global Circulating Tumor Cells Market Analysis and Forecast 2026-2032

21 December 2025202 pages

Choose your research edition.

Industry ResearchCirculating Tumor Cells Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Circulating Tumor Cells Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Circulating Tumor Cells Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Circulating Tumor Cells Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Circulating Tumor Cells Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

Global Circulating Tumor Cells main players are Menarini-Silicon Biosystems, Qiagen（Adnagen）, Clearbridge Biomedics, Celsee, Fluidigm. Global top five manufacturers hold a share over 30%.

Report Includes

Read the full market overview

This report presents an overview of global market for Circulating Tumor Cells, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Circulating Tumor Cells, also provides the revenue of main regions and countries. Of the upcoming market potential for Circulating Tumor Cells, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Circulating Tumor Cells revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Circulating Tumor Cells market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Circulating Tumor Cells revenue, projected growth trends, production technology, application and end-user industry.

Circulating Tumor Cells Segment by Company

Menarini-Silicon Biosystems

Qiagen (Adnagen)

Advanced Cell Diagnostics

ApoCell

Epic Sciences

Greiner Bio-one GmbH

Cynvenio

SurExamBio-Tech

Fluxion Biosciences

Ikonisys

Hangzhou Watson Biotech

Biocept

CytoTrack

Guangzhou Wondfo Biotech

Celsee

Clearbridge Biomedics

ANGLE plc

Circulating Tumor Cells Segment by Type

CTC Enrichment

CTC Detection

CTC Analysis

Circulating Tumor Cells Segment by Application

Breast Cancer

Prostate Cancer

Colorectal Cancer

Lung Cancer

Others

Circulating Tumor Cells Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cells market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cells and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cells.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Circulating Tumor Cells in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Circulating Tumor Cells company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Circulating Tumor Cells revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Circulating Tumor Cells Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CTC Enrichment Major Player Table 3. CTC Detection Major Player Table 4. CTC Analysis Major Player Table 5. Global Circulating Tumor Cells Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Breast Cancer Major Player Table 7. Prostate Cancer Major Player Table 8. Colorectal Cancer Major Player Table 9. Lung Cancer Major Player Table 10. Others Major Player Table 11. Circulating Tumor Cells Industry Trends Table 12. Circulating Tumor Cells Industry Drivers Table 13. Circulating Tumor Cells Industry Opportunities and Challenges Table 14. Circulating Tumor Cells Industry Restraints Table 15. Global Circulating Tumor Cells Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Circulating Tumor Cells Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Circulating Tumor Cells Market Share by Region (2021-2026) Table 18. Global Circulating Tumor Cells Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Circulating Tumor Cells Market Share by Region (2027-2032) Table 20. Global Circulating Tumor Cells Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Circulating Tumor Cells Revenue Market Share by Players (2021-2026) Table 22. Global Circulating Tumor Cells Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Circulating Tumor Cells Key Players Headquarters & Area Served Table 24. Global Circulating Tumor Cells Players, Product Type & Application Table 25. Global Circulating Tumor Cells Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Circulating Tumor Cells by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Circulating Tumor Cells Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Circulating Tumor Cells Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Circulating Tumor Cells Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Circulating Tumor Cells Revenue Market Share by Type (2021-2026) Table 32. Global Circulating Tumor Cells Revenue Market Share by Type (2027-2032) Table 33. Global Circulating Tumor Cells Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Circulating Tumor Cells Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Circulating Tumor Cells Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Circulating Tumor Cells Revenue Market Share by Application (2021-2026) Table 37. Global Circulating Tumor Cells Revenue Market Share by Application (2027-2032) Table 38. Menarini-Silicon Biosystems Company Information Table 39. Menarini-Silicon Biosystems Business Overview Table 40. Menarini-Silicon Biosystems Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Menarini-Silicon Biosystems Circulating Tumor Cells Product Portfolio Table 42. Menarini-Silicon Biosystems Recent Development Table 43. Qiagen (Adnagen) Company Information Table 44. Qiagen (Adnagen) Business Overview Table 45. Qiagen (Adnagen) Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Qiagen (Adnagen) Circulating Tumor Cells Product Portfolio Table 47. Qiagen (Adnagen) Recent Development Table 48. Advanced Cell Diagnostics Company Information Table 49. Advanced Cell Diagnostics Business Overview Table 50. Advanced Cell Diagnostics Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Advanced Cell Diagnostics Circulating Tumor Cells Product Portfolio Table 52. Advanced Cell Diagnostics Recent Development Table 53. ApoCell Company Information Table 54. ApoCell Business Overview Table 55. ApoCell Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. ApoCell Circulating Tumor Cells Product Portfolio Table 57. ApoCell Recent Development Table 58. Epic Sciences Company Information Table 59. Epic Sciences Business Overview Table 60. Epic Sciences Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Epic Sciences Circulating Tumor Cells Product Portfolio Table 62. Epic Sciences Recent Development Table 63. Greiner Bio-one GmbH Company Information Table 64. Greiner Bio-one GmbH Business Overview Table 65. Greiner Bio-one GmbH Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Greiner Bio-one GmbH Circulating Tumor Cells Product Portfolio Table 67. Greiner Bio-one GmbH Recent Development Table 68. Cynvenio Company Information Table 69. Cynvenio Business Overview Table 70. Cynvenio Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Cynvenio Circulating Tumor Cells Product Portfolio Table 72. Cynvenio Recent Development Table 73. SurExamBio-Tech Company Information Table 74. SurExamBio-Tech Business Overview Table 75. SurExamBio-Tech Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. SurExamBio-Tech Circulating Tumor Cells Product Portfolio Table 77. SurExamBio-Tech Recent Development Table 78. Fluxion Biosciences Company Information Table 79. Fluxion Biosciences Business Overview Table 80. Fluxion Biosciences Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Fluxion Biosciences Circulating Tumor Cells Product Portfolio Table 82. Fluxion Biosciences Recent Development Table 83. Ikonisys Company Information Table 84. Ikonisys Business Overview Table 85. Ikonisys Circulating Tumor Cells Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Ikonisys Circulating Tumor Cells Product Portfolio Table 87. Ikonisys Recent Development Table 88. Hangzhou Watson Biotech Company Information Table 89. Hangzhou Watson Biotech Business Overview Table 90. Hangzhou Watson Biotech Circulating Tumor Cells Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 91. Hangzhou Watson Biotech Circulating Tumor Cells Product Portfolio Table 92. Hangzhou Watson Biotech Recent Development Table 93. Biocept Company Information Table 94. Biocept Business Overview Table 95. Biocept Circulating Tumor Cells Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 96. Biocept Circulating Tumor Cells Product Portfolio Table 97. Biocept Recent Development Table 98. CytoTrack Company Information Table 99. CytoTrack Business Overview Table 100. CytoTrack Circulating Tumor Cells Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 101. CytoTrack Circulating Tumor Cells Product Portfolio Table 102. CytoTrack Recent Development Table 103. Guangzhou Wondfo Biotech Company Information Table 104. Guangzhou Wondfo Biotech Business Overview Table 105. Guangzhou Wondfo Biotech Circulating Tumor Cells Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 106. Guangzhou Wondfo Biotech Circulating Tumor Cells Product Portfolio Table 107. Guangzhou Wondfo Biotech Recent Development Table 108. Celsee Company Information Table 109. Celsee Business Overview Table 110. Celsee Circulating Tumor Cells Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 111. Celsee Circulating Tumor Cells Product Portfolio Table 112. Celsee Recent Development Table 113. Clearbridge Biomedics Company Information Table 114. Clearbridge Biomedics Business Overview Table 115. Clearbridge Biomedics Circulating Tumor Cells Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 116. Clearbridge Biomedics Circulating Tumor Cells Product Portfolio Table 117. Clearbridge Biomedics Recent Development Table 118. ANGLE plc Company Information Table 119. ANGLE plc Business Overview Table 120. ANGLE plc Circulating Tumor Cells Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 121. ANGLE plc Circulating Tumor Cells Product Portfolio Table 122. ANGLE plc Recent Development Table 123. North America Circulating Tumor Cells Revenue by Type (2021-2026) & (US$ Million) Table 124. North America Circulating Tumor Cells Revenue by Type (2027-2032) & (US$ Million) Table 125. North America Circulating Tumor Cells Revenue by Application (2021-2026) & (US$ Million) Table 126. North America Circulating Tumor Cells Revenue by Application (2027-2032) & (US$ Million) Table 127. North America Circulating Tumor Cells Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. North America Circulating Tumor Cells Revenue by Country (2021-2026) & (US$ Million) Table 129. North America Circulating Tumor Cells Revenue by Country (US$ Million) & (2027-2032) Table 130. Europe Circulating Tumor Cells Revenue by Type (2021-2026) & (US$ Million) Table 131. Europe Circulating Tumor Cells Revenue by Type (2027-2032) & (US$ Million) Table 132. Europe Circulating Tumor Cells Revenue by Application (2021-2026) & (US$ Million) Table 133. Europe Circulating Tumor Cells Revenue by Application (2027-2032) & (US$ Million) Table 134. Europe Circulating Tumor Cells Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. Europe Circulating Tumor Cells Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Circulating Tumor Cells Revenue by Country (US$ Million) & (2027-2032) Table 137. China Circulating Tumor Cells Revenue by Type (2021-2026) & (US$ Million) Table 138. China Circulating Tumor Cells Revenue by Type (2027-2032) & (US$ Million) Table 139. China Circulating Tumor Cells Revenue by Application (2021-2026) & (US$ Million) Table 140. China Circulating Tumor Cells Revenue by Application (2027-2032) & (US$ Million) Table 141. Asia Circulating Tumor Cells Revenue by Type (2021-2026) & (US$ Million) Table 142. Asia Circulating Tumor Cells Revenue by Type (2027-2032) & (US$ Million) Table 143. Asia Circulating Tumor Cells Revenue by Application (2021-2026) & (US$ Million) Table 144. Asia Circulating Tumor Cells Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia Circulating Tumor Cells Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 146. Asia Circulating Tumor Cells Revenue by Region (US$ Million) & (2021-2026) Table 147. Asia Circulating Tumor Cells Revenue by Region (US$ Million) & (2027-2032) Table 148. SAMEA Circulating Tumor Cells Revenue by Type (2021-2026) & (US$ Million) Table 149. SAMEA Circulating Tumor Cells Revenue by Type (2027-2032) & (US$ Million) Table 150. SAMEA Circulating Tumor Cells Revenue by Application (2021-2026) & (US$ Million) Table 151. SAMEA Circulating Tumor Cells Revenue by Application (2027-2032) & (US$ Million) Table 152. SAMEA Circulating Tumor Cells Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 153. SAMEA Circulating Tumor Cells Revenue by Country (2021-2026) & (US$ Million) Table 154. SAMEA Circulating Tumor Cells Revenue by Country (US$ Million) & (2027-2032) Table 155. Research Programs/Design for This Report Table 156. Authors List of This Report Table 157. Secondary Sources Table 158. Primary Sources List of Figures Figure 1. Circulating Tumor Cells Image Figure 2. Global Circulating Tumor Cells Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Circulating Tumor Cells Market Size Share 2021 VS 2025 VS 2032 Figure 4. CTC Enrichment Image Figure 5. CTC Detection Image Figure 6. CTC Analysis Image Figure 7. Global Circulating Tumor Cells Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Circulating Tumor Cells Market Size Share 2021 VS 2025 VS 2032 Figure 9. Breast Cancer Image Figure 10. Prostate Cancer Image Figure 11. Colorectal Cancer Image Figure 12. Lung Cancer Image Figure 13. Others Image Figure 14. Global Circulating Tumor Cells Market Size (US$ Million) & (2021-2032) Figure 15. Global Circulating Tumor Cells Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Circulating Tumor Cells Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Circulating Tumor Cells Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Circulating Tumor Cells Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Circulating Tumor Cells Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Circulating Tumor Cells Revenue Market Share by Type (2021-2032) Figure 22. Global Circulating Tumor Cells Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Circulating Tumor Cells Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Circulating Tumor Cells Revenue Market Share by Application (2021-2032) Figure 25. North America Circulating Tumor Cells Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Circulating Tumor Cells Revenue Share by Type (2021-2032) Figure 27. North America Circulating Tumor Cells Revenue Share by Application (2021-2032) Figure 28. North America Circulating Tumor Cells Revenue Share by Country (2021-2032) Figure 29. United States Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Circulating Tumor Cells Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Circulating Tumor Cells Revenue Share by Type (2021-2032) Figure 34. Europe Circulating Tumor Cells Revenue Share by Application (2021-2032) Figure 35. Europe Circulating Tumor Cells Revenue Share by Country (2021-2032) Figure 36. Germany Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Circulating Tumor Cells Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Circulating Tumor Cells Revenue Share by Type (2021-2032) Figure 46. China Circulating Tumor Cells Revenue Share by Application (2021-2032) Figure 47. Asia Circulating Tumor Cells Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Circulating Tumor Cells Revenue Share by Type (2021-2032) Figure 49. Asia Circulating Tumor Cells Revenue Share by Application (2021-2032) Figure 50. Asia Circulating Tumor Cells Revenue Share by Region (2021-2032) Figure 51. Japan Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Circulating Tumor Cells Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Circulating Tumor Cells Revenue Share by Type (2021-2032) Figure 59. SAMEA Circulating Tumor Cells Revenue Share by Application (2021-2032) Figure 60. SAMEA Circulating Tumor Cells Revenue Share by Country (2021-2032) Figure 61. Brazil Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Circulating Tumor Cells Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • CTC Enrichment
  • CTC Detection
  • CTC Analysis
Applications
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Others
Companies covered
  • Menarini-Silicon Biosystems
  • Qiagen (Adnagen)
  • Advanced Cell Diagnostics
  • ApoCell
  • Epic Sciences
  • Greiner Bio-one GmbH
  • Cynvenio
  • SurExamBio-Tech
  • Fluxion Biosciences
  • Ikonisys
  • Hangzhou Watson Biotech
  • Biocept
  • CytoTrack
  • Guangzhou Wondfo Biotech
  • Celsee
  • Clearbridge Biomedics
  • ANGLE plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Circulating Tumor Cells Market by Type
  3. 1.2.1 Global Circulating Tumor Cells Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CTC Enrichment
  5. 1.2.3 CTC Detection
  6. 1.2.4 CTC Analysis
  7. 1.3 Circulating Tumor Cells Market by Application
  8. 1.3.1 Global Circulating Tumor Cells Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Breast Cancer
  10. 1.3.3 Prostate Cancer
  11. 1.3.4 Colorectal Cancer
  12. 1.3.5 Lung Cancer
  13. 1.3.6 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Circulating Tumor Cells Market Dynamics
  1. 2.1 Circulating Tumor Cells Industry Trends
  2. 2.2 Circulating Tumor Cells Industry Drivers
  3. 2.3 Circulating Tumor Cells Industry Opportunities and Challenges
  4. 2.4 Circulating Tumor Cells Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Circulating Tumor Cells Market Perspective (2021-2032)
  2. 3.2 Global Circulating Tumor Cells Growth Trends by Region
  3. 3.2.1 Global Circulating Tumor Cells Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Circulating Tumor Cells Market Size by Region (2021-2026)
  5. 3.2.3 Global Circulating Tumor Cells Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Circulating Tumor Cells Revenue by Players
  2. 4.1.1 Global Circulating Tumor Cells Revenue by Players (2021-2026)
  3. 4.1.2 Global Circulating Tumor Cells Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Circulating Tumor Cells Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Circulating Tumor Cells Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Circulating Tumor Cells Key Players Headquarters & Area Served
  7. 4.4 Global Circulating Tumor Cells Players, Product Type & Application
  8. 4.5 Global Circulating Tumor Cells Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Circulating Tumor Cells Market CR5 and HHI
  11. 4.6.3 2025 Circulating Tumor Cells Tier 1, Tier 2, and Tier 3
5 Circulating Tumor Cells Market Size by Type
  1. 5.1 Global Circulating Tumor Cells Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Circulating Tumor Cells Revenue by Type (2021-2032)
  3. 5.3 Global Circulating Tumor Cells Revenue Market Share by Type (2021-2032)
6 Circulating Tumor Cells Market Size by Application
  1. 6.1 Global Circulating Tumor Cells Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Circulating Tumor Cells Revenue by Application (2021-2032)
  3. 6.3 Global Circulating Tumor Cells Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Menarini-Silicon Biosystems
  2. 7.1.1 Menarini-Silicon Biosystems Company Information
  3. 7.1.2 Menarini-Silicon Biosystems Business Overview
  4. 7.1.3 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Product Portfolio
  6. 7.1.5 Menarini-Silicon Biosystems Recent Developments
  7. 7.2 Qiagen (Adnagen)
  8. 7.2.1 Qiagen (Adnagen) Company Information
  9. 7.2.2 Qiagen (Adnagen) Business Overview
  10. 7.2.3 Qiagen (Adnagen) Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Qiagen (Adnagen) Circulating Tumor Cells Product Portfolio
  12. 7.2.5 Qiagen (Adnagen) Recent Developments
  13. 7.3 Advanced Cell Diagnostics
  14. 7.3.1 Advanced Cell Diagnostics Company Information
  15. 7.3.2 Advanced Cell Diagnostics Business Overview
  16. 7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Product Portfolio
  18. 7.3.5 Advanced Cell Diagnostics Recent Developments
  19. 7.4 ApoCell
  20. 7.4.1 ApoCell Company Information
  21. 7.4.2 ApoCell Business Overview
  22. 7.4.3 ApoCell Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  23. 7.4.4 ApoCell Circulating Tumor Cells Product Portfolio
  24. 7.4.5 ApoCell Recent Developments
  25. 7.5 Epic Sciences
  26. 7.5.1 Epic Sciences Company Information
  27. 7.5.2 Epic Sciences Business Overview
  28. 7.5.3 Epic Sciences Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Epic Sciences Circulating Tumor Cells Product Portfolio
  30. 7.5.5 Epic Sciences Recent Developments
  31. 7.6 Greiner Bio-one GmbH
  32. 7.6.1 Greiner Bio-one GmbH Company Information
  33. 7.6.2 Greiner Bio-one GmbH Business Overview
  34. 7.6.3 Greiner Bio-one GmbH Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Product Portfolio
  36. 7.6.5 Greiner Bio-one GmbH Recent Developments
  37. 7.7 Cynvenio
  38. 7.7.1 Cynvenio Company Information
  39. 7.7.2 Cynvenio Business Overview
  40. 7.7.3 Cynvenio Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Cynvenio Circulating Tumor Cells Product Portfolio
  42. 7.7.5 Cynvenio Recent Developments
  43. 7.8 SurExamBio-Tech
  44. 7.8.1 SurExamBio-Tech Company Information
  45. 7.8.2 SurExamBio-Tech Business Overview
  46. 7.8.3 SurExamBio-Tech Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  47. 7.8.4 SurExamBio-Tech Circulating Tumor Cells Product Portfolio
  48. 7.8.5 SurExamBio-Tech Recent Developments
  49. 7.9 Fluxion Biosciences
  50. 7.9.1 Fluxion Biosciences Company Information
  51. 7.9.2 Fluxion Biosciences Business Overview
  52. 7.9.3 Fluxion Biosciences Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Fluxion Biosciences Circulating Tumor Cells Product Portfolio
  54. 7.9.5 Fluxion Biosciences Recent Developments
  55. 7.10 Ikonisys
  56. 7.10.1 Ikonisys Company Information
  57. 7.10.2 Ikonisys Business Overview
  58. 7.10.3 Ikonisys Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Ikonisys Circulating Tumor Cells Product Portfolio
  60. 7.10.5 Ikonisys Recent Developments
  61. 7.11 Hangzhou Watson Biotech
  62. 7.11.1 Hangzhou Watson Biotech Company Information
  63. 7.11.2 Hangzhou Watson Biotech Business Overview
  64. 7.11.3 Hangzhou Watson Biotech Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Product Portfolio
  66. 7.11.5 Hangzhou Watson Biotech Recent Developments
  67. 7.12 Biocept
  68. 7.12.1 Biocept Company Information
  69. 7.12.2 Biocept Business Overview
  70. 7.12.3 Biocept Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Biocept Circulating Tumor Cells Product Portfolio
  72. 7.12.5 Biocept Recent Developments
  73. 7.13 CytoTrack
  74. 7.13.1 CytoTrack Company Information
  75. 7.13.2 CytoTrack Business Overview
  76. 7.13.3 CytoTrack Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  77. 7.13.4 CytoTrack Circulating Tumor Cells Product Portfolio
  78. 7.13.5 CytoTrack Recent Developments
  79. 7.14 Guangzhou Wondfo Biotech
  80. 7.14.1 Guangzhou Wondfo Biotech Company Information
  81. 7.14.2 Guangzhou Wondfo Biotech Business Overview
  82. 7.14.3 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Product Portfolio
  84. 7.14.5 Guangzhou Wondfo Biotech Recent Developments
  85. 7.15 Celsee
  86. 7.15.1 Celsee Company Information
  87. 7.15.2 Celsee Business Overview
  88. 7.15.3 Celsee Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Celsee Circulating Tumor Cells Product Portfolio
  90. 7.15.5 Celsee Recent Developments
  91. 7.16 Clearbridge Biomedics
  92. 7.16.1 Clearbridge Biomedics Company Information
  93. 7.16.2 Clearbridge Biomedics Business Overview
  94. 7.16.3 Clearbridge Biomedics Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Clearbridge Biomedics Circulating Tumor Cells Product Portfolio
  96. 7.16.5 Clearbridge Biomedics Recent Developments
  97. 7.17 ANGLE plc
  98. 7.17.1 ANGLE plc Company Information
  99. 7.17.2 ANGLE plc Business Overview
  100. 7.17.3 ANGLE plc Circulating Tumor Cells Revenue and Gross Margin (2021-2026)
  101. 7.17.4 ANGLE plc Circulating Tumor Cells Product Portfolio
  102. 7.17.5 ANGLE plc Recent Developments
8 North America
  1. 8.1 North America Circulating Tumor Cells Revenue (2021-2032)
  2. 8.2 North America Circulating Tumor Cells Revenue by Type (2021-2032)
  3. 8.2.1 North America Circulating Tumor Cells Revenue by Type (2021-2026)
  4. 8.2.2 North America Circulating Tumor Cells Revenue by Type (2027-2032)
  5. 8.3 North America Circulating Tumor Cells Revenue Share by Type (2021-2032)
  6. 8.4 North America Circulating Tumor Cells Revenue by Application (2021-2032)
  7. 8.4.1 North America Circulating Tumor Cells Revenue by Application (2021-2026)
  8. 8.4.2 North America Circulating Tumor Cells Revenue by Application (2027-2032)
  9. 8.5 North America Circulating Tumor Cells Revenue Share by Application (2021-2032)
  10. 8.6 North America Circulating Tumor Cells Revenue by Country
  11. 8.6.1 North America Circulating Tumor Cells Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Circulating Tumor Cells Revenue by Country (2021-2026)
  13. 8.6.3 North America Circulating Tumor Cells Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Circulating Tumor Cells Revenue (2021-2032)
  2. 9.2 Europe Circulating Tumor Cells Revenue by Type (2021-2032)
  3. 9.2.1 Europe Circulating Tumor Cells Revenue by Type (2021-2026)
  4. 9.2.2 Europe Circulating Tumor Cells Revenue by Type (2027-2032)
  5. 9.3 Europe Circulating Tumor Cells Revenue Share by Type (2021-2032)
  6. 9.4 Europe Circulating Tumor Cells Revenue by Application (2021-2032)
  7. 9.4.1 Europe Circulating Tumor Cells Revenue by Application (2021-2026)
  8. 9.4.2 Europe Circulating Tumor Cells Revenue by Application (2027-2032)
  9. 9.5 Europe Circulating Tumor Cells Revenue Share by Application (2021-2032)
  10. 9.6 Europe Circulating Tumor Cells Revenue by Country
  11. 9.6.1 Europe Circulating Tumor Cells Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Circulating Tumor Cells Revenue by Country (2021-2026)
  13. 9.6.3 Europe Circulating Tumor Cells Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Circulating Tumor Cells Revenue (2021-2032)
  2. 10.2 China Circulating Tumor Cells Revenue by Type (2021-2032)
  3. 10.2.1 China Circulating Tumor Cells Revenue by Type (2021-2026)
  4. 10.2.2 China Circulating Tumor Cells Revenue by Type (2027-2032)
  5. 10.3 China Circulating Tumor Cells Revenue Share by Type (2021-2032)
  6. 10.4 China Circulating Tumor Cells Revenue by Application (2021-2032)
  7. 10.4.1 China Circulating Tumor Cells Revenue by Application (2021-2026)
  8. 10.4.2 China Circulating Tumor Cells Revenue by Application (2027-2032)
  9. 10.5 China Circulating Tumor Cells Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Circulating Tumor Cells Revenue (2021-2032)
  2. 11.2 Asia Circulating Tumor Cells Revenue by Type (2021-2032)
  3. 11.2.1 Asia Circulating Tumor Cells Revenue by Type (2021-2026)
  4. 11.2.2 Asia Circulating Tumor Cells Revenue by Type (2027-2032)
  5. 11.3 Asia Circulating Tumor Cells Revenue Share by Type (2021-2032)
  6. 11.4 Asia Circulating Tumor Cells Revenue by Application (2021-2032)
  7. 11.4.1 Asia Circulating Tumor Cells Revenue by Application (2021-2026)
  8. 11.4.2 Asia Circulating Tumor Cells Revenue by Application (2027-2032)
  9. 11.5 Asia Circulating Tumor Cells Revenue Share by Application (2021-2032)
  10. 11.6 Asia Circulating Tumor Cells Revenue by Country
  11. 11.6.1 Asia Circulating Tumor Cells Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Circulating Tumor Cells Revenue by Country (2021-2026)
  13. 11.6.3 Asia Circulating Tumor Cells Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Circulating Tumor Cells Revenue (2021-2032)
  2. 12.2 SAMEA Circulating Tumor Cells Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Circulating Tumor Cells Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Circulating Tumor Cells Revenue by Type (2027-2032)
  5. 12.3 SAMEA Circulating Tumor Cells Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Circulating Tumor Cells Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Circulating Tumor Cells Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Circulating Tumor Cells Revenue by Application (2027-2032)
  9. 12.5 SAMEA Circulating Tumor Cells Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Circulating Tumor Cells Revenue by Country
  11. 12.6.1 SAMEA Circulating Tumor Cells Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Circulating Tumor Cells Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Circulating Tumor Cells Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst